Achilles Therapeutics PLC ADR


Prices are adjusted according to historical splits.

Achilles Therapeutics PLC ADR Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$0.079 billion
Book Value:
Revenue TTM:
$0.000 billion
Operating Margin TTM:
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Achilles Therapeutics PLC ADR had its IPO on 2021-03-31 under the ticker symbol ACHL.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Achilles Therapeutics PLC ADR has a staff strength of 0 employees.

Stock update

Shares of Achilles Therapeutics PLC ADR opened at $1.74 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $1.72 - $1.97, and closed at $1.93.

This is a +4.89% increase from the previous day's closing price.

A total volume of 25,389 shares were traded at the close of the day’s session.

In the last one week, shares of Achilles Therapeutics PLC ADR have slipped by -3.5%.

Achilles Therapeutics PLC ADR's Key Ratios

Achilles Therapeutics PLC ADR has a market cap of $0.079 billion, indicating a price to book ratio of 0.358 and a price to sales ratio of -.

In the last 12-months Achilles Therapeutics PLC ADR’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.070 billion. The EBITDA ratio measures Achilles Therapeutics PLC ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Achilles Therapeutics PLC ADR’s operating margin was 0% while its return on assets stood at -15.1% with a return of equity of -23.7%.

In Q2, Achilles Therapeutics PLC ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Achilles Therapeutics PLC ADR’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $6.35 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Achilles Therapeutics PLC ADR’s profitability.

Achilles Therapeutics PLC ADR stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of 1.549. Its price to sales ratio in the trailing 12-months stood at -.

Achilles Therapeutics PLC ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio

Achilles Therapeutics PLC ADR ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Achilles Therapeutics PLC ADR ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Achilles Therapeutics PLC ADR’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Achilles Therapeutics PLC ADR's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Achilles Therapeutics PLC ADR paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Achilles Therapeutics PLC ADR stock is currently trading at $1.93 per share. It touched a 52-week high of $7.49 and a 52-week low of $7.49. Analysts tracking the stock have a 12-month average target price of $14.17.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Achilles Therapeutics PLC ADR

The stock symbol (also called stock or share ticker) of Achilles Therapeutics PLC ADR is ACHL

The IPO of Achilles Therapeutics PLC ADR took place on 2021-03-31

Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))

Last Price
Agenus Inc (AGEN)

Most Active

Last Price
Apple Inc (AAPL)

Top Gainers

Last Price

Top Losers

Last Price
Air T, Inc (AIRTW)


Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.